Literature DB >> 10726444

[Chemotherapy in the treatment of ovarian carcinosarcoma].

G A Melilli1, G Di Vagno, G Cormio, P Greco, A Fontana, C Carriero, G Loverro, L Selvaggi.   

Abstract

Carcinosarcoma of the ovary is a rare neoplasm representing 1% of this organ malignancies. The disease appears almost exclusively in advanced stage having an unfavourable prognosis. Three patients affected by carcinosarcoma (MMMT) of the ovary admitted to our Operative Unit have been treated. All patients underwent surgery and subsequently chemotherapy. Two patients were affected by heterologous MMMT and were stage IV and IIIc respectively, the other one, affected by homologous MMMT, was stage IIIc. Stage IV patient was submitted to 6 cycles of CARBO + IFX + CDDP, second look and further 6 cycles of TAX. After 23 months she was submitted to colostomy for intestine occlusion. At the 35 months she died for cachexia and intestine occlusion. Stage IIIc heterologous patient was submitted to 6 cycles of CDDP + EPI + IFX + MESNA for 3 days; at 6 months from diagnosis she did not present any sign of disease. Stage IIIc homologous patient, affected by chronic renal insufficiency and submitted to dialysis, underwent 5 cycles of TAX and at 11 months from diagnosis presented partial response. Carcinosarcoma of the ovary, because of its rarity, and of the poor record of cases in the literature, is a much debated topic in particularitis complementary therapy. Opinions of the several authors are in contrast regarding the use of CHT + RT at the same time. Only RT after surgery does not seem to improve the survival of these patients. Personal experience, with the reported outlines, compared with survival, seems to confirm the use of CDDP and of IFX and to give new horizons to TAX, waiting for further findings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10726444

Source DB:  PubMed          Journal:  Minerva Ginecol        ISSN: 0026-4784


  1 in total

1.  Carcinosarcoma of the ovary.

Authors:  M A Harris; L M Delap; P S Sengupta; P M Wilkinson; R S Welch; R Swindell; J H Shanks; G Wilson; R J Slade; K Reynolds; G C Jayson
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.